Dr. Jacobson on the Significance of CD19-Targeted CAR T-Cell Therapy in B-Cell Malignancies

Video

Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.

Caron Jacobson, MD, a senior physician and medical director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.

The introduction of CD19-targeted CAR T-cell therapy has transformed the treatment of patients with CD19-positive cancers, ​says Jacobson, adding that the effects of CAR T-cell therapy have been felt across hematologic malignancies.

As the​se products continue in development, research efforts are seeking ways to apply this technology to other diseases that do not express CD19​, Jacobson explains. 

With a number of ongoing clinical trials ​underway, the field is hopeful that these products will receive new ​regulatory indications so that the benefits observed in B-cell malignancies can translate to other tumor types, Jacobson concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Sven Moller-Tank, PhD, a senior director at Regeneron
Alexey Danilov, MD, PhD, the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, codirector of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Related Content
© 2025 MJH Life Sciences

All rights reserved.